Methotrexate Treatment Suppresses Monocytes in Nonresponders to Pneumococcal Conjugate Vaccine in Rheumatoid Arthritis Patients

Figure 1

Composite antibody response in healthy controls, RA 0DMARD, and RA MTX groups, after immunization with 13-valent pneumococcal conjugate vaccine (PCV13). Composite antibody response represents the sum of change in pneumococcal serotype-specific IgG concentrations (μg/mL), for 11 capsular serotypes included in PCV13, pre- to postvaccination. Nonresponders are depicted in grey and the remaining are responders (defined as ≥ twofold increase in antibody titers in ≥ 6 serotypes pre- to postvaccination). Kruskal-Wallis with Dunn’s multiple comparisons test was used to calculate level of significance. Data are presented with medians. ab: antibody; HC: healthy control; 0DMARD: without disease-modifying antirheumatic drug treatment; MTX: methotrexate; RA: rheumatoid arthritis. Antibody titers were measured in 10 HC, 8 0DMARD and 9 MTX patients.